Closed

T2 PI25 ISCIII

Barcelona Ref. 2026/034

Call for a T2 PI25 ISCIII the Oncogenesis and Antitumor Drug group. Deadline: March 18th, 2026, 3:00 pm

About the Group

The Oncogenesis and Antitumor Drugs group is a multidisciplinary team whose research aimed to develop and biologically validate new targeted nanomedicine to treat cancer. The main research lines in the lab are:

  • Development of novel animal models of disseminated disease in solid tumours and haematological neoplasms for the mechanistic study of metastases and preclinical drug development.
  • Identification of prognostic biomarkers in head and neck squamous cell carcinoma and their functional validation in vivo.
  • Development of nanoconjugates for targeted delivery of antitumour drugs or toxins to metastasis stem cells. The Group is within the Research Institute of the Hospital de la Santa Creu i Sant Pau (IIB- Sant Pau), which has been accredited as a Health Research Institute by the Health Institute Carlos III (ISCIII) and as a CERCA Center by the Generalitat of Catalonia. Additionally, the group is part of the Network Biomedical Research Center in Bioengineering, Biomaterials and Nanomedicine of the Health Institute Carlos III (CIBER-BBN, CB06/01/1031) and has been recognized as a Consolidated Research Group by the Generalitat of Catalonia since 2005 (2021SGR-01140).

Essential requirements

  • Minimum qualification: Bachelor’s degree in Biochemistry, Biotechnology, or a related field
  • Oral and written proficiency in Catalonia’s two official languages (Catalan and Spanish), or, if not currently met, the successful candidate must demonstrate— or commit to obtaining within a maximum of one year—an adequate command of both
  • Intermediate level of English (written and spoken)
  • Intermediate proficiency in standard office software (Excel, Word, PowerPoint, etc.) Skills will be valued
  • MSc degree in Molecular Biology, Biomedicine, or a related field
  • Completed laboratory animal experimentation course (functions A, B and C)"
  • Proven experience in mammalian cell culture
  • Experience with proteomics workflows and/or data analysis
  • Experience with molecular biology techniques (western blotting, PCR/qPCR, ELISA, cloning)
  • Experience with statistical software (GraphPad Prism, SPSS, R)
  • Track record of scientific output (peer-reviewed publications and/or conference poster presentations)

Functions

  • The successful candidate will provide technical support to the project “Dissecting the cellular crosstalk of PDGFRβ+ cancer-associated fibroblasts as a tool to modulate therapeutic response in microsatellite-stable (MSS) colorectal cancer.” Responsibilities will include, but will not be limited to:
  • Subcutaneous and orthotopic implantation of colorectal cancer cells in mice; drug administration; monitoring of tumor progression; tissue collection/harvesting
  • Cell line maintenance; tumor dissociation; western blotting; qPCR
  • Sample preparation for proteomics studies (cells and tissues)
  • Maintaining accurate and complete laboratory records
  • Preparation of solutions and routine laboratory reagents

Offered

  • Contract linked to the PROJECT Dissecting the cellular crosstalk of PDGFR+ cancer-associated fibroblasts as a tool to modulate the therapeutic response in microsatellite stable colorectal cancer.
  • Full-time position (37,5h/week; annual workload: of 1.627,50h)
  • Remuneration in accordance with ISCIII salary tables
  • Research group: Oncogenesis and Antitumor Drug Group

Documentation and deadline for submission

Interested parties should preferably deliver the documentation (1) in PDF, by e-mail to the Management of the Santa Creu i Sant Pau Hospital Research Institute Foundation, address ir_seleccio@santpau.cat , indicating the reference 2026/034:

(1) Application letter and updated Curriculum Vitae

At the request of the Santa Creu i Sant Pau Hospital Research Institute Foundation, the candidates must present the documentation accrediting the merits mentioned in the curriculum vitae. Applications will be resolved within a maximum period of one month from the end of the deadline for submission of documentation. At the end of this period, without having been notified of an express resolution, the interested parties will be entitled to understand that their applications have been rejected. Santa Creu i Sant Pau Hospital Research Institute Foundation may declare this call for applications closed if, according to its criteria, the candidates does not meet the conditions that the Institution considers necessary to fill the position. The interpretation of the requirements and their enforceability to the candidates will be exclusive to the Santa Creu i Sant Pau Hospital Research Institute Foundation.

The deadline for submitting applications will end on March 18th, 2026, at 3:00 p.m.

Barcelona, Tel: 93 291 90 50, NIF: G-60136934,

Apply to this offer

Accepted File Extensions: PDF, DOC, DOCX, ODT, TXT (max 10 MB)
Accepted File Extensions: PDF, DOC, DOCX, ODT, TXT (max 10 MB)
Text to Identify Refresh CAPTCHA